Fintel reports that on October 31, 2025, Macquarie upgraded their outlook for Core Scientific, Inc. – Equity Right (OTCPK:CORZR) from Neutral to Outperform.
Analyst Price Forecast Suggests 79.95% Downside
As of October 30, 2025, the average one-year price target for Core Scientific, Inc. – Equity Right is $0.06/share. The forecasts range from a low of $0.05 to a high of $0.09. The average price target represents a decrease of 79.95% from its latest reported closing price of $0.32 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Core Scientific, Inc. – Equity Right is 614MM, an increase of 83.63%. The projected annual non-GAAP EPS is -0.01.
What is the Fund Sentiment?
There are 1 funds or institutions reporting positions in Core Scientific, Inc. – Equity Right. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to CORZR is 0.00%, an increase of 86.80%. Total shares owned by institutions decreased in the last three months by 33.67% to 328K shares.
What are Other Shareholders Doing?
BlackRock Credit Strategies Fund holds 328K shares. In its prior filing, the firm reported owning 495K shares , representing a decrease of 50.76%. The firm decreased its portfolio allocation in CORZR by 86.80% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.